Parexel management changes
Executive Summary
Parexel COO Carl Spalding will retire effective June 30; the COO position will remain unfilled for the foreseeable future, the contract research organization said. President-Clinical Research Services Michael Woehler is promoted to Exec VP, and President-Perceptive Informatics Mark Goldberg will take Woehler's former title; Goldberg will also continue to oversee perceptive informatics. Kurt Brykman is promoted to president-consulting and medical marketing services...
You may also be interested in...
EU’s SCCS Finds Endocrine-Disrupting Evidence Inconclusive In UV Filter Reassessments
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
US FDA Urges COVID-19 Transmission Risk Mitigation In Cell And Gene Therapy Manufacturing
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.
COVID-19: US Acted To Beat Other Countries To Next 1.25M Doses Of Regeneron Cocktail
Move was meant to preempt others’ efforts to secure the next six months of Regeneron’s COVID-19 antibody therapeutic.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: